# HEAL Initiative: Rapidly Assessing the Public Health Impact of Emerging Opioid Threats (UG1 - Clinical Trial Not Allowed)

Source: https://welltoldgrants.com/grants/rfa-da-23-045-heal-initiative-rapidly-assessing-the-public-health-impact/  
Official notice: https://www.grants.gov/search-results-detail/341849

> National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on February 2, 2023.

| Field | Value |
|---|---|
| Opportunity number | RFA-DA-23-045 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | February 2, 2023 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.213, 93.273, 93.279 |

## Who can apply

- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

## What the grant funds

The need to rapidly develop methods to assess the prevalence / health impact of emerging illicit drugs has never been greater. Illicit chemists are marketing potent drugs of abuse taken from deep wells of scientific and patent literature, which we can expect to continue to yield new drugs for many years. Over the last few years, fentanyl/fentalogs (fentanyl-related opioids) have flooded the illicit opioid market, which has complicated patient stabilization / harm reduction, and caused mortality rates to skyrocket. Even understanding the drugs being used is difficult due to unstandardized analytical methods, and urine test strip kit variabilities. When test strips do detect fentalogs they simply indicate fentanyl and clinicians base treatment on this homogenous grouping. However, it is unclear that the addictive or mortality risk of fentalogs are generalizable. Initially fentanyl was reported to be long-lasting and poorly antagonizable, but such reports diminished when carfentanil, an ultrapotent and long-lasting fentalog, diminished in drug supplies. Now, ultrapotent "nitazene" opioids are on the market and a lack of validated analytical protocols and standards, has meant these drugs are over-looked in most jurisdictions. Nitazene urine test strips do not yet exist and so clinicians are ill-equipped to recognize nitazenes and respond appropriately. Users certainly do not know whether nitazenes (or fentalogs) are illicit purchased drugs. This FOA promotes development and distribution of tools to detect nitazenes in the necessary range of settings needed to enable appropriately calculated responses. Additionally, this RFA builds-in funds to allow awardees to rapidly bring their discoveries and expertise to bear on the future generations of threats that are surely coming

## Questions people ask

### Is RFA-DA-23-045 still open?

No. It closed on February 2, 2023.

### Who can apply for HEAL Initiative: Rapidly Assessing the Public Health Impact of Emerging Opioid Threats (UG1 - Clinical Trial Not Allowed)?

National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for HEAL Initiative: Rapidly Assessing the Public Health Impact of Emerging Opioid Threats (UG1 - Clinical Trial Not Allowed)?

Closed February 2, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### Who has been funded under RFA-DA-23-045?

NIH RePORTER lists 1 project funded under RFA-DA-23-045 in fiscal 2023 to 2026, at 1 institution.

### Who has won Research and Training in Complementary and Integrative Health grants before?

The largest recipients over five fiscal years were Yale Univ, The General Hospital Corporation, Duke University. The program made 653 awards worth $575 million in that time.